Target Name: CCNA1
NCBI ID: G8900
Review Report on CCNA1 Target / Biomarker Content of Review Report on CCNA1 Target / Biomarker
CCNA1
Other Name(s): CT146 | Cyclin A1, transcript variant 1 | CCNA1_HUMAN | Cyclin A1 | CCNA1 variant 1 | Cyclin-A1 | cyclin A1 | testicular tissue protein Li 34

Identifying Potential Drug Targets and Biomarkers for CCNA1

The Comprehensive Community Network Analysis (CCNA) is a network analysis technique that has been widely used in the field of network biology to study the interactions between genes and proteins in a cell. One of the most promising applications of CCNA is the identification of potential drug targets and biomarkers. In this article, we will explore theCCNA1 (CT146), a protein that has been identified as a potential drug target and biomarker in several studies.

Potential Drug Target

The CCNA1 protein is a member of the CCNA family, which are known for their ability to detect and quantify gene expression in a cell. The CCNA1 protein has been shown to play a role in the regulation of gene expression in various organisms, including humans.

One of the key functions of the CCNA1 protein is its ability to interact with the RNA polymerase II (RNA-II) complex. RNA-II is a complex that is responsible for transcribing DNA into RNA in the cell. By interacting with RNA-II, the CCNA1 protein has been shown to regulate the expression of target genes.

In addition to its role in regulating gene expression, the CCNA1 protein has also been shown to play a role in the regulation of cellular processes such as cell division, apoptosis, and autophagy. These processes are important for the survival and growth of the cell, and are often targeted by drugs that are used to treat various diseases.

Potential Biomarker

The CCNA1 protein has also been shown to be a potential biomarker for several diseases, including cancer. In cancer, the expression of CCNA1 has been shown to be altered in various ways, including increased, decreased, or altered levels of the protein. These changes in CCNA1 expression can be used as a biomarker for the diagnosis, prognosis, and treatment of cancer.

One of the key advantages of using CCNA1 as a biomarker for cancer is its ability to be expressed in various cell types, including cancer cells. This makes it a useful marker for the detection and treatment of cancer in a variety of settings, including primary and metastatic stages of the disease.

Another advantage of CCNA1 as a biomarker for cancer is its ability to be affected by the treatment of cancer. Many drugs that are used to treat cancer are designed to inhibit the expression of CCNA1, with the goal of limiting the growth and survival of cancer cells. By measuring the expression of CCNA1 before and after treatment, it may be possible to determine the effectiveness of a given drug.

Conclusion

In conclusion, the CCNA1 protein has been shown to be a potential drug target and biomarker in several studies. Its ability to interact with the RNA-II complex and its role in regulating cellular processes such as cell division, apoptosis, and autophagy make it an attractive target for drug development. Additionally, its ability to be expressed in various cell types and its response to cancer treatment make it a promising biomarker for the diagnosis, prognosis, and treatment of cancer. Further research is needed to fully understand the role of CCNA1 in these processes and its potential as a drug target and biomarker.

Protein Name: Cyclin A1

Functions: May be involved in the control of the cell cycle at the G1/S (start) and G2/M (mitosis) transitions. May primarily function in the control of the germline meiotic cell cycle and additionally in the control of mitotic cell cycle in some somatic cells

The "CCNA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCNA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24